Press release
Sandhoff Disease Pipeline Analysis Highlights Emerging Therapies and Active Industry Players Through 2025, says DelveInsight
Sandhoff Disease Pipeline
Explore the most recent therapeutic developments and evolving treatment strategies in the Sandhoff Disease pipeline. Access DelveInsight's in-depth pipeline analysis today!
@ Sandhoff Disease Pipeline Outlook - https://www.delveinsight.com/sample-request/sandhoff-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Highlights from the Sandhoff Disease Pipeline Report
• DelveInsight's Sandhoff Disease Pipeline report showcases a dynamic and competitive landscape, with over five companies actively advancing more than five pipeline therapies for Sandhoff Disease.
• Prominent Sandhoff Disease players include IntraBio, Sanofi, Polaryx Therapeutics, Azafaros, among others.
• Notable Sandhoff Disease pipeline candidates include IB1001, Zavesca (Miglustat), TSHA-101, Miglustat, and additional emerging therapies.
Stay informed with the latest Sandhoff Disease pipeline developments. Gain valuable insights into ongoing clinical trials, novel therapies, and key industry players with DelveInsight
@ Sandhoff Disease Treatment Drugs - https://www.delveinsight.com/sample-request/sandhoff-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Drugs in the Sandhoff Disease Pipeline
IB1001: IntraBio
IB1001 (N-acetyl-L-leucine) is an orally administered modified amino acid. Preclinical studies have demonstrated that N-acetyl-L-leucine is the pharmacologically active isomer of N-acetyl-DL-leucine, capable of restoring neuronal function and delaying disease progression across multiple neurological pathways. Its multimodal mechanism of action includes modulation of glucose and antioxidant metabolism, reduction of lysosomal storage, and suppression of neuroinflammation in the cerebellum, ultimately helping to reduce neuronal cell death. IntraBio is currently conducting a multinational, multicenter, open-label, rater-blinded Phase II clinical study to evaluate the safety and efficacy of IB1001 in patients with GM2 Gangliosidosis, including Tay-Sachs and Sandhoff Disease.
Venglustat: Sanofi
Venglustat is an innovative oral investigational therapy designed to slow disease progression by inhibiting the abnormal accumulation of glycosphingolipids (GSLs). Excess GSL buildup is linked to cellular dysfunction and disease advancement in several rare disorders. Venglustat is currently undergoing Phase III clinical evaluation for the treatment of Sandhoff Disease.
Key Insights Offered by the Sandhoff Disease Pipeline Report
• The report provides in-depth information on companies developing Sandhoff Disease therapies, including an overview of each company's pipeline portfolio.
• It categorizes therapeutic candidates into early-, mid-, and late-stage development phases for Sandhoff Disease treatment.
• The analysis includes both active and inactive (dormant or discontinued) Sandhoff Disease pipeline programs.
• Pipeline drugs are assessed based on development stage, route of administration, target receptor, monotherapy or combination use, mechanism of action, and molecular class.
• The report also offers a comprehensive review of strategic collaborations, including company-to-company and industry-academia partnerships, along with licensing deals and funding activities shaping the future Sandhoff Disease market.
Discover cutting-edge therapies and clinical research shaping the Sandhoff Disease marketed and pipeline drug landscape. Access DelveInsight's detailed report now @ New Sandhoff Disease Drugs - https://www.delveinsight.com/sample-request/sandhoff-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Sandhoff Disease Key Companies
IntraBio, Sanofi, Polaryx Therapeutics, Azafaros, and other emerging players.
The Sandhoff Disease Pipeline Report also evaluates pipeline therapies based on route of administration (ROA), including:
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Sandhoff Disease pipeline products are further classified by molecule type, such as:
• Monoclonal antibodies
• Peptides
• Polymers
• Small molecules
• Gene therapies
Gain insights into the future of Sandhoff Disease management. Understand market drivers, challenges, and innovation trends with DelveInsight's expert analysis
@ Sandhoff Disease Market Drivers and Barriers - https://www.delveinsight.com/sample-request/sandhoff-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Sandhoff Disease Pipeline Report
• Geographical Coverage: Global
• Key Companies: IntraBio, Sanofi, Polaryx Therapeutics, Azafaros, and others
• Pipeline Therapies: IB1001, Zavesca (Miglustat), TSHA-101, Miglustat, and additional candidates
• Therapeutic Assessment by Product Type: Monotherapy, Combination Therapy, and Mono/Combination
• Therapeutic Assessment by Development Stage: Discovery, Preclinical, Phase I, Phase II, and Phase III
Stay updated on the latest Sandhoff Disease therapies and clinical advancements. Download DelveInsight's comprehensive pipeline report today! @ Sandhoff Disease Companies, Key Products and Unmet Needs - https://www.delveinsight.com/sample-request/sandhoff-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Sandhoff Disease Pipeline Analysis Highlights Emerging Therapies and Active Industry Players Through 2025, says DelveInsight here
News-ID: 4339814 • Views: …
More Releases from DelveInsight Business Research
Spinal Cord Injury Market Poised for Sustained Growth Amid Advancements in Treat …
DelveInsight's "Spinal Cord Injury Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Spinal Cord Injury, historical and forecasted epidemiology as well as the Spinal Cord Injury market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Get a Free sample for the Spinal Cord Injury Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav
Some of the key facts of the…
Pulmonary Arterial Hypertension Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Pulmonary Arterial Hypertension pipeline constitutes 55+ key companies continuously working towards developing 50+ Pulmonary Arterial Hypertension treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Pulmonary Arterial Hypertension Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pulmonary Arterial…
Irritable Bowel Syndrome Pipeline 2026: In-depth Clinical Trials Analysis and Em …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Irritable Bowel Syndrome pipeline constitutes 15+ key companies continuously working towards developing 20+ Irritable Bowel Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Irritable Bowel Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The…
Pancreatic Cancer Market Growth Outlook 2036: Epidemiology, Pipeline Therapies, …
The Pancreatic Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Pancreatic Cancer market dynamics.
DelveInsight's "Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of Pancreatic Cancer, historical and forecasted epidemiology as well as the Pancreatic Cancer market trends in the United States, EU5 (Germany,…
More Releases for Sandhoff
Gene Therapy Advances Offer New Hope for Sandhoff Disease Patients | Sandhoff Di …
👉 Sandhoff Disease Therapeutics Market Size and Forecast
👉 Sandhoff Disease Therapeutics Market is valued at a significant CAGR during the forecast period (2026-2033). As per DataM Intelligence Database.
DataM Intelligence has released a new research report titled "Sandhoff Disease Therapeutics Market Size 2026", providing a comprehensive analysis of the market's current landscape and future outlook. The report delivers in-depth insights into key factors such as regional growth trends, market segmentation, CAGR…
Sandhoff Disease Market to Reach USD 72.4 Million by 2034 Driven
Pune, India - December 2025 - The global Sandhoff Disease Market, valued at USD 29.6 million in 2024, is expected to reach USD 72.4 million by 2034, growing at a 9.4% CAGR (2025-2034), according to Exactitude Consultancy. Market growth is driven by increasing R&D in rare neurodegenerative disorders, rising investment in gene therapy, and supportive regulatory incentives for orphan drug development.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/72045
Market Summary
The…
Sandhoff Disease Market to Reach USD 1.2 Billion by 2034
Sandhoff disease is a rare, inherited lysosomal storage disorder caused by mutations in the HEXB gene, leading to a deficiency in the beta-hexosaminidase A and B enzymes. This deficiency results in the accumulation of GM2 gangliosides within nerve cells, causing progressive neurodegeneration. Sandhoff disease presents in various forms-infantile, juvenile, and adult-onset-with the infantile type being the most severe and often fatal by early childhood.
Download Full PDF Sample Copy of Market…
Sandhoff Disease Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Sandhoff Disease Pipeline Insight 2025" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Sandhoff Disease pipeline landscape. It covers the Sandhoff Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sandhoff Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Sandhoff Disease pipeline products in this space.
Discover the latest drugs…
Sandhoff Disease Market Size, Share, Trends, Growth 2024-2032
The Sandhoff disease market size was valued at USD 10.18 billion in 2023, driven growing interest in gene therapy as a potential curative approach across the major markets. The market size is anticipated to grow at a CAGR of 5.87% during the forecast period of 2024-2032 and attain a value of USD 17 billion by 2032.
Sandhoff Disease:
Sandhoff disease is a rare, inherited genetic disorder characterized by the harmful accumulation of…
Sandhoff Disease Treatment Market Analysis: Understanding Trends, Players, and P …
"Sandhoff Disease Treatment Market Is Growing At A Steady Cagr During Forecast Period".
With thorough company profiles, recent developments, and other information, the Sandhoff Disease Treatment Market Report provides an in-depth analysis of major trends, motivating reasons, obstacles, segmentation, regulatory policies, and important players. The Sandhoff Disease Treatment Market Report offers a thorough synopsis of the product portfolio, including product development, planning, and positioning of products with emerging technologies, impending opportunities,…
